Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. The company's core expertise centers on targeting G-protein coupled receptors (GPCRs) with small molecules possessing specifically tailored pharmacology. Crinetics' first commercial product, PALSONIFY (paltusotine), is the first once-daily oral treatment approved by both the U.S. FDA and EMA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. The company's pipeline includes atumelnant, a late-stage investigational ACTH receptor antagonist in Phase 3 development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682, a nonpeptide drug conjugate targeting somatostatin receptor 2 (SST2) expressing neuroendocrine and solid tumors. Additional discovery programs target thyroid stimulating hormone (TSH), parathyroid hormone (PTH), somatostatin receptor 3 (SST3), growth hormone (GH), and GPCR-targeted oncology indications. In July 2026, Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics for $85.00 per share in cash. Updated Aug 3, 2026